⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Official Title: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Study ID: NCT05245500

Interventions

MRTX1719

Study Description

Brief Summary: This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Detailed Description: This first-in-human clinical trial will begin with an exploration of MRTX1719 dose and regimen. As potentially viable regimens are identified, Phase 1b expansion cohorts may be implemented to ensure sufficient safety experience, PK information, compare food effect and relative bioavailability between capsules and tablets, and early evidence of clinical activity are available to recommend Phase 2 regimens. In Phase 2, separate cohorts of patients by histological diagnosis and/or baseline characteristics will be evaluated for the clinical activity and efficacy of MRTX1719.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Mayo Clinic, Phoenix, Arizona, United States

Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

Mayo Clinic, Jacksonville, Florida, United States

Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Mayo Clinic, Rochester, Minnesota, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

NorthShore Hematology Oncology Associates P.C New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States

Sarah Cannon Research Institute, Nashville, Tennessee, United States

MD Anderson Cancer Center, Houston, Texas, United States

Oncology Consultants, P.A., Houston, Texas, United States

START Center for Cancer Care, San Antonio, Texas, United States

NEXT Virginia, Fairfax, Virginia, United States

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Contact Details

Name: Bristol-Myers Squibb, MD

Affiliation: Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: